Hansa Biopharma AB (FRA:24H) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 10, 2026)


FRA:24H Hansa Biopharma AB FRA:24H
55 GF Score
Price €3.07
GF Value €2.07
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Hansa Biopharma AB Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Hansa Biopharma AB's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

FRA:24H vs VRTX, REGN, ALNY: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Hansa Biopharma AB's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hansa Biopharma AB Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Hansa Biopharma AB's Margin of Safety % (DCF Dividends Based) falls into.


FRA:24H
55GF Score
Hansa Biopharma AB FRA:24H
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Hansa Biopharma AB (FRA:24H) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of €3.07 is trading 48.5% above its estimated GF Value™ of €2.07. GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.

Key valuation signals for FRA:24H:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: €2.07 vs. price of €3.07 (48.5% above fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the FRA:24H stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
55GF Score

Get the complete analysis for FRA:24H

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.07
Price
€2.07
GF Value